Liposomal Drug Delivery Devices Market Seen Hitting $9.49 Billion by 2030

The liposomal drug delivery devices market is projected to rise from $5.34 billion in 2025 to $9.49 billion by 2030, driven by cancer prevalence, targeted therapies and expanding use of advanced drug delivery platforms. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Liposomal drug delivery devices are central to targeted treatment strategies that can improve drug delivery and reduce side effects. - The market’s growth signals rising demand for cancer therapies, biologics, vaccines and other precision medicine approaches. - Faster adoption could shape how drug makers design treatments to limit toxicity and improve outcomes.

What happened: - The Business Research Company released a market report on liposomal drug delivery devices on August 14, 2026. - The report says the market will grow from $5.34 billion in 2025 to $6.01 billion in 2026. - The report projects the market will reach $9.49 billion by 2030. - The forecast implies a 12.4% CAGR from 2025 to 2026 and a 12.1% CAGR through 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period.

The details: - The report links recent growth to advances in nanotechnology-based drug delivery systems. - Rising cancer prevalence is also boosting demand. - Broader availability of injectable drug formulations is supporting adoption. - Greater use of liposomal antifungal treatments is contributing to market expansion. - Increased investment in pharmaceutical research is another growth driver. - Future growth is expected to come from targeted cancer therapies and personalized medicine. - Expanded use of advanced drug delivery platforms is part of the forecast. - More funding for biologics and vaccines is expected to add momentum. - Drug makers are also focusing on reducing drug-related toxicity. - The report highlights growth in targeted delivery mechanisms, pegylated liposomal formulations, oncology applications, liposomal vaccines and antifungal agents, plus controlled drug release technologies. - Liposomal drug delivery devices are microscopic spherical structures that transport drug molecules to specific sites in the body. - These carriers are designed to improve targeting and reduce side effects. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis. - A free sample and the full report are available through the company’s sample page and the full market report.

Between the lines: - The report ties the market outlook to a broader shift toward therapies that are more precise and less toxic. - The cancer burden is a major structural driver, with the World Health Organization reporting about 20 million new cases in 2022 and projecting 35 million by 2050. - That projected 77% increase helps explain why drug-delivery platforms aimed at targeted treatment are drawing more attention.

What's next: - The market’s next phase will likely be shaped by oncology pipelines, biologics development and continued investment in targeted delivery technologies. - Asia-Pacific’s growth could narrow the gap with North America if adoption accelerates across drug makers and treatment centers. - The Business Research Company is also promoting updated 2026 reports with expanded visual intelligence and forecasting tools.

The bottom line: - Liposomal drug delivery devices are moving from a niche technology to a faster-growing part of the broader precision medicine market.